Last update 21 Nov 2024
huCART19-IL18(University of Pennsylvania)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), IL18R1 agonists(Interleukin 18 receptor agonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with huCART19-IL18(University of Pennsylvania)Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Cancers
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) Alone and When Co-administered With Humanized Anti-CD19 Chimeric Antigen Receptor Redirected T Cells (huCART19) In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
100 Clinical Results associated with huCART19-IL18(University of Pennsylvania)
Login to view more data
100 Translational Medicine associated with huCART19-IL18(University of Pennsylvania)
Login to view more data
100 Patents (Medical) associated with huCART19-IL18(University of Pennsylvania)
Login to view more data
100 Deals associated with huCART19-IL18(University of Pennsylvania)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Phase 1 | US | 06 May 2021 | |
| Chronic Lymphocytic Leukemia | Phase 1 | US | 06 May 2021 | |
| Non-Hodgkin Lymphoma | Phase 1 | US | 06 May 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04684563 (EHA2024) Manual  | Phase 1 | 21 | (qpbrqrvnbr) = ihcjlebtsz qsckgfbrvi (rvkhroehdg ) View more | Positive | 14 May 2024 | ||
Not Applicable | Lymphoma CD19+ | 16 | cuailsrnfr(esivydrixv) = zylfuvbzzm cdzzfuopfh (nraafyvrfl, 53 - 97) View more | Positive | 09 Jun 2023 | ||
NCT04684563 (ASH2022) Manual | Phase 1 | 9 | (efilhrreqd) = Other non-hematologic G3 or higher adverse events at least possibly related to huCART19-IL18 included infections in 2 (25%), hypotension in 2 (25%), and AST elevation in 1 (12.5%) in the setting of CRS. lznrwazveb (xveuradqvh ) | Positive | 15 Nov 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free